CLINICAL PHARMACOKINETICS OF PROCAINAMIDE

[31] KARLSSON E, 1977, BRIT J CLIN PHARMACO, V4, P632

[32] ANTIARRHYTHMIC PROPHYLAXIS WITH PROCAINAMIDE IN ACUTE MYOCARDIAL INFARCTION [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1969, 281 (23) : 1253 - &

[33] SERUM PROCAINAMIDE LEVELS AS THERAPEUTIC GUIDES [J]. CLINICAL PHARMACOKINETICS, 1977, 2 (06) : 389 - 402

[34] PHARMACOKINETICS OF PROCAINAMIDE IN MAN [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 179 (JUL6) : 370 - +

[35] PROCAINAMIDE DOSAGE SCHEDULES, PLASMA CONCENTRATIONS, AND CLINICAL EFFECTS [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 215 (09) : 1454 - +

[36] BIOCHEMICAL AND GENETIC FACTORS REGULATING DILANTIN METABOLISM IN MAN [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 179 (JUL6) : 704 - &

[37] KUTT H, 1968, JAMA-J AM MED ASSOC, V203, P167

[38] LEE WK, 1976, CLIN PHARMACOL THER, V19, P508

[39] DISEASE AND ACETYLATION POLYMORPHISM [J]. CLINICAL PHARMACOKINETICS, 1977, 2 (03) : 182 - 197

[40] MARK LESTER C, 1951, JOUR PHARMACOL AND EXPTL THERAP, V102, P5

[31] KARLSSON E, 1977, BRIT J CLIN PHARMACO, V4, P632

[32] ANTIARRHYTHMIC PROPHYLAXIS WITH PROCAINAMIDE IN ACUTE MYOCARDIAL INFARCTION [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1969, 281 (23) : 1253 - &

[33] SERUM PROCAINAMIDE LEVELS AS THERAPEUTIC GUIDES [J]. CLINICAL PHARMACOKINETICS, 1977, 2 (06) : 389 - 402

[34] PHARMACOKINETICS OF PROCAINAMIDE IN MAN [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 179 (JUL6) : 370 - +

[35] PROCAINAMIDE DOSAGE SCHEDULES, PLASMA CONCENTRATIONS, AND CLINICAL EFFECTS [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 215 (09) : 1454 - +

[36] BIOCHEMICAL AND GENETIC FACTORS REGULATING DILANTIN METABOLISM IN MAN [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 179 (JUL6) : 704 - &

[37] KUTT H, 1968, JAMA-J AM MED ASSOC, V203, P167

[38] LEE WK, 1976, CLIN PHARMACOL THER, V19, P508

[39] DISEASE AND ACETYLATION POLYMORPHISM [J]. CLINICAL PHARMACOKINETICS, 1977, 2 (03) : 182 - 197

[40] MARK LESTER C, 1951, JOUR PHARMACOL AND EXPTL THERAP, V102, P5